Romina J. Brando-Fernandez
B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Neutralizing antibodies in the intestinal mucosa are essential to control gastrointestinal infection by Shiga toxin-producing Escherichia coli.
Journal: mLife
Published: October 14, 2024
Nasal immunization with H7 flagellin protects mice against hemolytic uremic syndrome secondary to Escherichia coli O157:H7 gastrointestinal infection.
Journal: Frontiers in cellular and infection microbiology
Published: January 13, 2023
Detection of plasma anti-lipopolysaccharide (LPS) antibodies against enterohemorrhagic Escherichia coli (EHEC) in asymptomatic kindergarten teachers from Buenos Aires province.
Journal: Revista Argentina de microbiologia
Published: November 17, 2022
Etiological diagnosis of post-diarrheal hemolytic uremic syndrome (HUS): humoral response contribution.
Journal: Pediatric nephrology (Berlin, Germany)
Published: February 17, 2022
Differential Outcome between BALB/c and C57BL/6 Mice after Escherichia coli O157:H7 Infection Is Associated with a Dissimilar Tolerance Mechanism.
Journal: Infection and immunity
Published: January 15, 2021
Mechanisms involved in the adaptation of Escherichia coli O157:H7 to the host intestinal microenvironment.
Journal: Clinical science (London, England : 1979)
Published: August 03, 2020
Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
Journal: Clinical science (London, England : 1979)
Published: April 16, 2020
Role of Shiga Toxins in Cytotoxicity and Immunomodulatory Effects of Escherichia coli O157:H7 during Host-Bacterial Interactions in vitro.
Journal: Toxins
Published: November 08, 2019
Relevance of Bacteriophage 933W in the Development of Hemolytic Uremic Syndrome (HUS).
Journal: Frontiers in microbiology
Published: October 01, 2018
Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity.
Journal: Vaccine
Published: October 24, 2017
Last Updated: 09/26/2026